Enhancing the Bioavailability of Low-Solubility Compounds
Low aqueous solubility resulting in poor oral bioavailability of drug candidates is recognised as an increasingly common challenge facing the pharmaceutical industry. An estimated 25% to 30% of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in therapeutic and economic opportunity.
In this complimentary case study webcast, Bend Research discusses amorphous dispersion based formulations highlighting:
- Outlining the need for increased solubility and rapid absorption
- Assessing the impact of enteric dispersions on absorption rate
- Developing rapidly dissolving amorphous formulations
- Pursuing formulation and process development for amorphous drugpolymer nanoparticles
Director of Business Development
Bend Research, Inc
* = required.